These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 29121759)

  • 1. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies.
    Watti H; Dahal K; Zabher HG; Katikaneni P; Modi K; Abdulbaki A
    Int J Cardiol; 2017 Dec; 249():66-72. PubMed ID: 29121759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
    J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Sakurai R; Burazor I; Bonneau HN; Kaneda H
    J Interv Cardiol; 2017 Oct; 30(5):457-464. PubMed ID: 28804959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
    Khan MS; Memon MM; Usman MS; Alnaimat S; Khan SU; Khan AR; Yamani N; Fugar S; Mookadam F; Krasuski RA; Doukky R
    Am J Cardiovasc Drugs; 2019 Oct; 19(5):465-476. PubMed ID: 30828769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
    Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
    Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
    Bundhun PK; Shi JX; Huang F
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):80. PubMed ID: 29233189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
    Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
    Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis.
    Singh S; Singh M; Grewal N; Khosla S
    Am J Ther; 2016; 23(1):e52-62. PubMed ID: 26448337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
    Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database.
    Effron MB; Nair KV; Molife C; Keller SY; Page RL; Simeone JC; Murphy B; Nordstrom BL; Zhu Y; McCollam PL; Vetrovec GW
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):129-141. PubMed ID: 29222628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Society Guidelines on Trends in Use of Newer P2Y
    Mohamed MO; Kontopantelis E; Alasnag M; Abid L; Banerjee A; Sharp ASP; Bourantas C; Sirker A; Curzen N; Mamas MA
    J Am Heart Assoc; 2024 May; 13(9):e034414. PubMed ID: 38700032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
    Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):561-574. PubMed ID: 32816142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
    Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
    Koshy AN; Giustino G; Sartori S; Hooda A; Feng Y; Snyder C; Dasgupta S; Kumar KR; Krishnamoorthy-Melarcode P; Sweeny J; Khera S; Serrao GW; Sharma R; Dangas G; Kini AS; Mehran R; Sharma SK
    EuroIntervention; 2023 Mar; 18(15):1244-1253. PubMed ID: 36660810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.